36m
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
Initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant for the treatment ...
Initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); submission expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results